Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Pregnancy and breastfeeding: Maxiliv Tablet should not be used during pregnancy and breastfeeding unless the potential benefit outweighs the risks
Conclusion (Summary first) GLP-1 receptor agonists may increase the risk of cholelithiasis and gallbladder disease The risk is tending to be higher with drugs and dosages that cause greater weight loss The mechanism is reduced gallbladder motility + rapid weight loss Cholelithiasis risk: Overall picture In large-scale meta-analyses, GLP-1 receptor agonist use Gallbladder disease risk: RR 1.37 Cholelithiasis: RR 1.27 Cholecystitis: RR 1.36 1) It is important to note that while this is a significant increase, the "absolute risk is not high." Differences in risk by drug Liraglutide (Victoza) The increase in cholelithiasis risk is relatively clear In the SCALE trials, Gallstone-related events: 2.3% vs 1.0% (placebo) 2) Increased in the group with greater weight loss Semaglutide (Ozempic/Wegovy) In the STEP trials, etc., Gallbladder disease increasing trend (approx
Product Details Available sizes: 10 mg Form: Lyophilized powder Testing: Independent third-party testing COA: Available by lot Origin: Manufactured in the USA Packaging: Sealed vial Storage: Refrigerate between 2C and 8C
Dandelion Root: Promotes bile flow and digestive elimination
Look for gradual weight loss (0.5-1kg per week), improved energy levels, better blood sugar control, and reduced food noise
US$ 24.49
US$ 29.03
US$ 29.27
US$ 21.78
US$ 25.60
